Visual outcomes of age-related macular degeneration patients undergoing intravitreal ranibizumab monotherapy in an urban population

Khadijah Basheer, Evelyn Mensah, Tina Khanam, Neda Minakaran Ophthalmology Department, Central Middlesex Hospital, London, UK Aim: To compare the visual outcomes of an urban population with age-related macular degeneration (AMD) undergoing ranibizumab monotherapy to the results from major clinical...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Basheer K, Mensah E, Khanam T, Minakaran N
Formato: article
Lenguaje:EN
Publicado: Dove Medical Press 2015
Materias:
Acceso en línea:https://doaj.org/article/1d29dcaede704a64b05da8279d4ce59c
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:doaj.org-article:1d29dcaede704a64b05da8279d4ce59c
record_format dspace
spelling oai:doaj.org-article:1d29dcaede704a64b05da8279d4ce59c2021-12-02T01:06:09ZVisual outcomes of age-related macular degeneration patients undergoing intravitreal ranibizumab monotherapy in an urban population1177-5483https://doaj.org/article/1d29dcaede704a64b05da8279d4ce59c2015-05-01T00:00:00Zhttp://www.dovepress.com/visual-outcomes-of-age-related-macular-degeneration-patients-undergoin-peer-reviewed-article-OPTHhttps://doaj.org/toc/1177-5483Khadijah Basheer, Evelyn Mensah, Tina Khanam, Neda Minakaran Ophthalmology Department, Central Middlesex Hospital, London, UK Aim: To compare the visual outcomes of an urban population with age-related macular degeneration (AMD) undergoing ranibizumab monotherapy to the results from major clinical trials.Procedures: Prospective data was collected from 164 wet AMD patients receiving intravitreal ranibizumab. Visual acuities were obtained with the Early Treatment Diabetic Retinopathy Study chart. All patients underwent a loading phase of three monthly treatments of ranibizumab. Patients were monitored monthly using a retreatment criterion. Treatment was further individualized by sequentially lengthening follow-up intervals when stable.Results: At 12 and 24 months, respectively, the percentage of eyes that maintained vision was 91% and 88.6%. We found that 20.3% of eyes had improved vision at 12 months and 20% at 24 months. At 12 months, 8.3% of eyes’ vision worsened and 12% worsened at 24 months.Conclusion: Individualized ranibizumab monotherapy is effective in preserving vision in wet AMD and follows the same trends as the pivotal trials. Keywords: visual acuity, comparison of age-related macular degeneration treatment trials, choroidal neovascular membraneBasheer KMensah EKhanam TMinakaran NDove Medical PressarticleOphthalmologyRE1-994ENClinical Ophthalmology, Vol 2015, Iss default, Pp 959-965 (2015)
institution DOAJ
collection DOAJ
language EN
topic Ophthalmology
RE1-994
spellingShingle Ophthalmology
RE1-994
Basheer K
Mensah E
Khanam T
Minakaran N
Visual outcomes of age-related macular degeneration patients undergoing intravitreal ranibizumab monotherapy in an urban population
description Khadijah Basheer, Evelyn Mensah, Tina Khanam, Neda Minakaran Ophthalmology Department, Central Middlesex Hospital, London, UK Aim: To compare the visual outcomes of an urban population with age-related macular degeneration (AMD) undergoing ranibizumab monotherapy to the results from major clinical trials.Procedures: Prospective data was collected from 164 wet AMD patients receiving intravitreal ranibizumab. Visual acuities were obtained with the Early Treatment Diabetic Retinopathy Study chart. All patients underwent a loading phase of three monthly treatments of ranibizumab. Patients were monitored monthly using a retreatment criterion. Treatment was further individualized by sequentially lengthening follow-up intervals when stable.Results: At 12 and 24 months, respectively, the percentage of eyes that maintained vision was 91% and 88.6%. We found that 20.3% of eyes had improved vision at 12 months and 20% at 24 months. At 12 months, 8.3% of eyes’ vision worsened and 12% worsened at 24 months.Conclusion: Individualized ranibizumab monotherapy is effective in preserving vision in wet AMD and follows the same trends as the pivotal trials. Keywords: visual acuity, comparison of age-related macular degeneration treatment trials, choroidal neovascular membrane
format article
author Basheer K
Mensah E
Khanam T
Minakaran N
author_facet Basheer K
Mensah E
Khanam T
Minakaran N
author_sort Basheer K
title Visual outcomes of age-related macular degeneration patients undergoing intravitreal ranibizumab monotherapy in an urban population
title_short Visual outcomes of age-related macular degeneration patients undergoing intravitreal ranibizumab monotherapy in an urban population
title_full Visual outcomes of age-related macular degeneration patients undergoing intravitreal ranibizumab monotherapy in an urban population
title_fullStr Visual outcomes of age-related macular degeneration patients undergoing intravitreal ranibizumab monotherapy in an urban population
title_full_unstemmed Visual outcomes of age-related macular degeneration patients undergoing intravitreal ranibizumab monotherapy in an urban population
title_sort visual outcomes of age-related macular degeneration patients undergoing intravitreal ranibizumab monotherapy in an urban population
publisher Dove Medical Press
publishDate 2015
url https://doaj.org/article/1d29dcaede704a64b05da8279d4ce59c
work_keys_str_mv AT basheerk visualoutcomesofagerelatedmaculardegenerationpatientsundergoingintravitrealranibizumabmonotherapyinanurbanpopulation
AT mensahe visualoutcomesofagerelatedmaculardegenerationpatientsundergoingintravitrealranibizumabmonotherapyinanurbanpopulation
AT khanamt visualoutcomesofagerelatedmaculardegenerationpatientsundergoingintravitrealranibizumabmonotherapyinanurbanpopulation
AT minakarann visualoutcomesofagerelatedmaculardegenerationpatientsundergoingintravitrealranibizumabmonotherapyinanurbanpopulation
_version_ 1718403302051282944